Statin therapy in peritoneal dialysis patients: Effects beyond lipid lowering

International Urology and Nephrology

Volumn 40, Issue 1, 2008, Pages 165-170

  Paraskevas, Kosmas I ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

End stage kidney disease; Haemodialysis; Kidney function; Peritoneal dialysis; Statins

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN; ROSUVASTATIN;

CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DISEASE COURSE; DOSE KIDNEY FUNCTION RELATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DYSLIPIDEMIA; HEMODIALYSIS; HIGH RISK PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; LOW DRUG DOSE; MORBIDITY; MORTALITY; PERITONEAL DIALYSIS; PRESCRIPTION; REVIEW; RISK REDUCTION; UNSPECIFIED SIDE EFFECT; URINARY EXCRETION;

ANTICHOLESTEREMIC AGENTS; C-REACTIVE PROTEIN; CHRONIC DISEASE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; KIDNEY DISEASES; LIPIDS; PERITONEAL DIALYSIS; PYRROLES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 41549099286     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-007-9307-6     Document Type: Review

References (81)

1. Ahmad M, Shah H, Pliakogiannis T et al (2007) Prevention of membrane damage in patient on peritoneal dialysis with new peritoneal dialysis solutions. Int Urol Nephrol 39:299-312
2. de Jonge H, Bammens B, Lemahieu W et al (2006) Comparison of peritoneal dialysis and haemodialysis after renal transplant failure. Nephrol Dial Transplant 21:1669-1674
3. Soleymanian T, Raman S, Shannaq FN et al (2006) Survival and morbidity of HIV patients on hemodialysis and peritoneal dialysis: One center's experience and review of the literature. Int Urol Nephrol 38:331-338
4. Ahmad M (2007) Continuous ambulatory peritoneal dialysis in patients with renal failure due to multiple myeloma. Int Urol Nephrol 39:629-633
5. Yang X, Fang W, Kothari J et al (2007) Clinical outcomes of elderly patients undergoing chronic peritoneal dialysis: Experiences from one center and a review of the literature. Int Urol Nephrol 39(4):1295-1302
6. Davies SJ (2001) Peritoneal dialysis in the patient with a failing renal allograft. Perit Dial Int 21:S280-S284
7. Salonen T, Reina T, Oksa H et al (2007) Alternative strategies to evaluate the cost-effectiveness of peritoneal dialysis and hemodialysis. Int Urol Nephrol 39:289-298
8. Wasserfallen JB, Moinat M, Halabi G et al (2006) Satisfaction of patients on chronic haemodialysis and peritoneal dialysis. Swiss Med Wkly 136:210-217
9. Apostolou T (2007) Quality of life in the elderly patients on dialysis. Int Urol Nephrol 39:679-683
10. Trbojevic JB, Nesic VB, Stojimirovic BB (2001) Quality of life of elderly patients undergoing continuous ambulatory peritoneal dialysis. Peri Dial Int 21:S300-S303
11. Horinek A, Misra M (2004) Does residual renal function decline more rapidly in hemodialysis than in peritoneal dialysis? How good is the evidence? Adv Perit Dial 20:137-140
12. Chandna SM, Farrington K (2004) Residual renal function: Considerations on its importance and preservation in dialysis patients. Semin Dial 17:196-201
13. Piraino B (2006) Peritoneal dialysis infections recommendations. Contrib Nephrol 150:181-186
14. Thodis E, Passadakis P, Lyrantzopoulos N et al (2005) Peritoneal catheters and related infections. Int Urol Nephrol 37:379-393
15. Lui SL, Yip T, Tse KC et al (2007) Tuberculous lymphadenitis in patients undergoing continuous ambulatory peritoneal dialysis. Int Urol Nephrol 39:971-974
16. Bonifati C, Pansini F, Tones DD et al (2006) Antimicrobial agents and catheter-related interventions to prevent peritonitis in peritoneal dialysis: Using evidence in the context of clinical practice. Int J Artif Organs 29:41-49
17. Bender FH, Bernardini J, Piraino B (2006) Prevention of infectious complications in peritoneal dialysis: Best demonstrated practices. Kidney Int Suppl 103:S44-S54
18. [No authors listed] (2003) USRDS: The United States Renal Data System. Am J Kidney Dis 42(6 Suppl 5):1-230
19. Katneni R, Hedayati SS (2007) Central venous catheter-related bacteremia in chronic hemodialysis patients: Epidemiology and evidence-based management. Nat Clin Pract Nephrol 3:256-266
20. Lok CE (2006) Avoiding trouble down the line: The management and prevention of hemodialysis catheter-related infections. Adv Chronic Kidney Dis 13:225-244
21. Yildirir A, Müderrisoglu H (2004) Non-lipid effects of statins: emerging new indications. Curr Vasc Pharmacol 2:309-318
22. Paraskevas KI, Athyros VG, Briana DD et al (2007) Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures. Curr Drug Targets 8:942-951
23. Calabrò P, Yeh ET (2005) The pleiotropic effects of statins. Curr Opin Cardiol 20:541-546
24. Paoletti R, Bolego C, Cignarella A (2005) Lipid and non-lipid effects of statins. Handb Exp Pharmacol 170:365-388
25. Paraskevas KI, Hamilton G, Mikhailidis DP (2007) Statins: An essential component in the management of carotid artery disease. J Vasc Surg 46:373-386
26. Navaneethan SD, Shrivastava R (2004) HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev 4:CD004289
27. Abo-Zenah H, Sabry A, Farouk A et al (2007) The impact of haemodialysis-associated variables on lipid profile in Egyptian haemodialysis population. Int Urol Nephrol 39:609-618
28. Fox CS, Longenecker JC, Powe NR et al (2004) Undertreatment of hyperlipidemia in a cohort of United States kidney dialysis patients. Clin Nephrol 61:299-307
29. Molitch ME (2006) Management of dyslipidemias in patients with diabetes and chronic kidney disease. Clin J Am Soc Nephrol 1:1090-1099
30. Senti M, Romero R, Pedro-Botet J et al (1992) Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int 41:1394-1399
31. Cheung AK, Wu LL, Kablitz C et al (1993) Atherogenic lipids and lipoproteins in hemodialysis patients. Am J Kidney Dis 22:271-276
32. Cressman MD, Heyka RJ, Paganini EP et al (1992) Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86:475-482
33. Kronenberg F, König P, Neyer U et al (1995) Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 6:110-120
34. Siamopoulos KC, Elisaf MS, Bairaktari HT et al (1995) Lipid parameters including lipoprotein (a) in patients undergoing CAPD and hemodialysis. Perit Dial Int 15:342-347
35. Appel G (1991) Lipid abnormalities in renal disease. Kidney Int 39:169-183
36. Canziani ME, Cendoroglo Neto M, Saragoca MA et al (1995) Hemodialysis versus continuous ambulatory peritoneal dialysis: Effects on the heart. Artif Organs 19:241-244
37. Abbott KC, Trespalacios FC, Taylor AJ et al (2003) Atrial fibrillation in chronic dialysis patients in the United States: Risk factors for hospitalization and mortality. BMC 4:1
38. Maiorca R, Cancarini GC, Brunori G et al (1993) Morbidity and mortality of CAPD and hemodialysis. Kidney Int Suppl 40:S4-S15
39. Hufnagel G, Michel C, Vrtovsnik F et al (2000) Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis. Nephrol Dial Transplant 15:684-688
40. Saltissi D, Westhuyzen J, Morgan C et al (2006) Efficacy, safety and tolerability of atorvastatin in dyslipidemic subjects with advanced (non-nephrotic) and endstage chronic renal failure. Clin Exp Nephrol 10:201-209
41. Harris KP, Wheeler DC, Chong CC (2002) A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. Kidney Int 61:1469-1474
42. Foley RN, Parfrey PS, Sarnak MJ (1998) Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 9:S16-S23
43. Maitra S, Sekercioglu N, Baloch S et al (2007) Causes of death in older peritoneal dialysis patients - can we depend on registry reports? Int Urol Nephrol 39:345-350
44. Soubassi LP, Chiras TC, Papadakis ED et al (2006) Incidence and risk factors of coronary heart disease in elderly patients on chronic hemodialysis. Int Urol Nephrol 38:795-800
45. Stenvinkel P, Pecoits-Filho R, Lindholm B (2003) Coronary artery disease in end-stage renal disease: No longer a simple plumbing problem. J Am Soc Nephrol 14:1927-1939
46. Ridker PM, Rifai N, Rose L et al (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347:1557-1565
47. Herzig KA, Purdie DM, Chang W et al (2001) Is C-reactive protein a useful predictor of outcome in peritoneal dialysis patients? J Am Soc Nephrol 12:814-821
48. Iseki K, Tozawa M, Yoshi S et al (1999) Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant 14:1956-1960
49. Wei M, Bargman JM, Oreopoulos DG (2007) Factors related to erythropoietin hypo-responsiveness in patients on chronic peritoneal dialysis. Int Urol Nephrol 39:935-940
50. Field KM (2005) Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels. Pharmacotherapy 25:1365-1377
51. Prasad K (2006) C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 24:33-50
52. Holm T, Andreassen AK, Ueland T et al (2001) Effect of pravastatin on plasma markers of inflammation and peripheral endothelial function in male heart transplant recipients. Am J Cardiol 87:815-818
53. Stenvinkel P (2005) Inflammation in end-stage renal disease - A fire that burns within. Contrib Nephrol 149:185-199
54. Stenvinkel P, Rodríguez-Ayala E, Massy ZA et al (2006) Statin treatment and diabetes affect myeloperoxidase activity in maintenance hemodialysis patients. Clin J Am Soc Nephrol 1:281-287
55. Panichi V, Paoletti S, Mantuano E et al (2006) In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrol Dial Transplant 21:337-344
56. Mantuano E, Santi S, Filippi C et al (2007) Simvastatin and fluvastatin reduce interleukin-6 and interleukin-8 lipopolysaccharide (LPS) stimulated production by isolated human monocytes from chronic kidney disease patients. Biomed Pharmacother 61:360-365
57. Tsirpanlis G, Boufidou F, Manganas S et al (2004) Treatment with fluvastatin rapidly modulates, via different pathways, and in dependence on the baseline level, inflammation in hemodialysis patients. Blood Purif 22:518-524
58. Seliger SL, Weiss NS, Gillen DL et al (2002) HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61:297-304
59. Mason NA, Bailie GR, Satayathum S et al (2005) HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 45:119-126
60. Wanner C, Krane V, März W et al (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238-248
61. LaRosa JC, Grundy SM, Waters DD et al (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352:1425-1435
62. Waters DD, LaRosa JC, Barter P et al (2006) Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J Am Coll Cardiol 48:1793-1799
63. Fellström B, Holdaas H, Jardine AG et al (2007) Effect of rosuvastatin on outcomes in chronic haemodialysis patients: Baseline data from the AURORA study. Kidney Blood Press Res 30:314-322
64. Baigent C, Landry M (2003) Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 84:S207-S210
65. Campese VM, Park J (2007) HMG-CoA reductase inhibitors and the kidney. Kidney Int 71:1215-1222
66. D'Amico G (2006) Statins and renal diseases: From primary prevention to renal replacement therapy. J Am Soc Nephrol 17(4 Suppl 2):S148-S152
67. Vidt DG, Harris S, McTaggart F et al (2006) Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am J Cardiol 97:1602-1606
68. Shah S, Paparello J, Danesh FR (2005) Effects of statin therapy on the progression of chronic kidney disease. Adv Chronic Kidney Dis 12:187-195
69. Locatelli F, Del Vecchio L, Pozzoni P (2005) Clinical benefits of slowing the progression of renal failure. Kidney Int Suppl 99:S152-S156
70. Haslinger B, Goedde MF, Toet KH et al (2002) Simvastatin increases fibrinolytic activity in human peritoneal mesothelial cells independent of cholesterol lowering. Kidney Int 62:1611-1619
71. Dobbie JW (1992) Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 12:14-27
72. Lund L, Jønler M (2007) Peritoneal dialysis catheter placement: is laparoscopy an option? Int Urol Nephrol 39:625-628
73. Law MR, Wald NJ, Rudnicka AR (2003) Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326:1423-1427
74. Choudhry NK, Avorn J (2005) Over-the-counter statins. Ann Intern Med 142:910-913
75. Sica DA, Gehr TW (2002) 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: Considerations in the renal failure patient. Curr Opin Nephrol Hypertens 11:123-133
76. Stern RH, Yang BB, Horton M et al (1997) Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin. J Clin Pharmacol 37:816-819
77. Appel-Dingemanse S, Smith T, Merz M (2002) Pharmacokinetics of fluvastatin in subjects with renal impairment and nephrotic syndrome. J Clin Pharmacol 42:312-318
78. Gehr TW, Sica DA, Slugg PH et al (1997) The pharmacokinetics of pravastatin in patients on chronic hemodialysis. Eur J Clin Pharmacol 53:117-121
79. Igel M, Sudhop T, von Bergmann K (2001) Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 57:357-364
80. Gowdak LH, Arantes RL, de Paula FJ et al (2007) Underuse of American College of Cardiology/American Heart Association Guidelines in hemodialysis patients. Ren Fail 29:559-565
81. Seliger SL, Stehman-Breen CO (2003) Are HMG-CoA reductase inhibitors underutilized in dialysis patients? Semin Dial 16:179-185